Figure 1.

Screening of an FDA-approved drug library. Dot plot of all included 786 compounds screened at a concentration of 1 µM after 72 h to identify substances capable of suppressing DNA synthesis of PHA-stimulated PBMCs. Highlighted are the initial hits (red), comprising compounds which are not FDA-assigned as immunosuppressive or anti-neoplastic drugs (right), but inhibited DNA synthesis >50% (horizontal cut off line).